Person: KARAHASAN, AYŞEGÜL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KARAHASAN
First Name
AYŞEGÜL
Name
26 results
Search Results
Now showing 1 - 10 of 26
Publication Open Access Evaluation of BioFire Filmarray panel for respiratory pathogens: A demographic and clinical analysis in Istanbul, Turkey(2023-05-01) KARAHASAN, AYŞEGÜL; ÇİMŞİT, NURİ ÇAGATAY; Karahasan A., Çimşit N. Ç.We aimed to analyze the distribution of respiratory pathogens(RP) detected by a multiplex PCR-based method (BioFire Diagnostics, USA) among patients with suspected respiratory tract infections (RTI) and to evaluate the demographic, clinical and radiological characteristics of infected individuals . RP were detected in 1621/6376 (25.4%) of the samples in the years 2018-2020. Rhinovirus/enterovirus (RV/EV) were the most commonly detected pathogens (38.1%) followed by influenza A and B viruses (21%) and parainfluenza virus (PIV) (9.5%). Single pathogen was detected in 1361 (84%) and multi pathogens in 260 (16%) of 1621 samples. At least one comorbidity was present in 379 (30.5%) of the patients. Fever was the most common sign followed by cough and dyspnea. Thorax CT was present in 426 of 1243 RP positive patients (34.3%). Any radiological findings was found significantly related for a specific pathogen. No medication was given to 52.9% whereas antibiotics in 35.7% and antivirals in 3.8% of the patients. Film Array panel as a multiplex PCR test is not used rationally in our hospital and results were not dramatically improve management of RTI. A better communication between clinician and microbiologist is required for efficient use of laboratory and rational use of antimicrobials.Publication Metadata only Polimeraz zincir reaksiyonu temelli tiplendirme yöntemleri: AP-PCR, ERIC-PCR, REP-PCR, PCR-RFLP(Nobel Yayın Dağıtım, 2022-11-01) KARAHASAN, AYŞEGÜL; Karahasan A.; Otlu, Barış; Durmaz, RızaPublication Metadata only Incidence of MIS-C and the Comorbidity Scores in Pediatric COVID-19 Cases(2021) KARAHASAN, AYŞEGÜL; Ergenc, Zeynep; Kepenekli, Eda; Çetin, Ece; Ersoy, Ayşenur; Korkmaz, Billur; Selçik, Raziye; Sarınoglu, Rabia Can; Karahasan, AysegülBACKGROUND: We aimed to determine the incidence of multisystem ınflammatory syndrome in children (MIS-C) in pediatric coronavirus disease 2019 (COVID-19) cases and to define the relationships between the need for hospitalization, the development of MIS-C, and Charlson (CCI) and Pediatric comorbidity index (PCI) scores. METHODS: All pediatric COVID-19 cases between March 25, 2020, and December 28, 2020, in the Marmara University Pendik Training and Research Hospital were enrolled. Patients who needed hospitalization were determined. Hospital records were reexamined to identify those diagnosed as having MIS-C. CCI and PCI were used to validate the comorbidity status. RESULTS: Among 2055 pediatric COVID-19 cases, 1340 were included in the study. Two hundred thirteen patients (15.9%) had at least one comorbidity. All the patients or their parents were interviewed about the need for hospitalization, except for the acute period. Six patients had MIS-C, which corresponds to a MIS-C incidence of 0.4%. The need for hospitalization increased in the patients with comorbidities (p<0.05). No correlation was found between the comorbidity scores and the development of MIS-C. The need for hospitalization increased in the patients with CCI scores of ≥2 and PCI scores of ≥4 (p<0.05). CONCLUSIONS: Our study is the first to examine the incidence of MIS-C, which was 0.4%, by long-term follow-up of pediatric COVID-19 cases and to demonstrate that the CCI and PCI can be used to predict the need for hospitalization and prognosis of pediatric patients with COVID-19.Publication Metadata only İdrar kültürlerinde kontaminasyon oranları düşürülebilir mi(2023-05-01) KARAHASAN, AYŞEGÜL; Karahasan A.Publication Metadata only Predictors of eradication failure at first isolation of MRSA in cystic fibrosis patients(EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2020) KARAHASAN, AYŞEGÜL; Mursaloglu, Huseyin Hakan; Akin, Can; Yilmaz, Cansu; Ergenekon, Pinar; Gokdemir, Yasemin; Eralp, Ela Erdem; Karakoc, Fazilet; Karahasan, Aysegul; Karadag, BulentPublication Metadata only Xpert MTB/Ultra assay: Handle with care(W.B. Saunders Ltd, 2020) KARAHASAN, AYŞEGÜL; Sarınoğlu R.C., Duman N., Ünlü N., Yıldızeli S.O., Yagci A.K.[No abstract available]Publication Open Access The Association of Thyroid Hormone Changes with Inflammatory Status and Prognosis in COVID-19(HINDAWI LTD, 2021-08-13) KARAHASAN, AYŞEGÜL; Yazan, Ceyda Dincer; Ilgin, Can; Elbasan, Onur; Apaydin, Tugce; Dashdamirova, Saida; Yigit, Tayfun; Sili, Uluhan; Yagci, Aysegul Karahasan; Sirikci, Onder; Haklar, Goncagul; Gozu, HulyaBackground. COVID-19 infection may have multiorgan effects in addition to effects on the lungs and immune system. Recently, studies have found thyroid function abnormalities in COVID-19 cases which were interpreted as euthyroid sick syndrome (ESS) or destructive thyroiditis. Therefore, in this study, we aimed to evaluate the thyroid function status and thyroid autoimmunity in COVID-19 patients. Material and Method. 205 patients were included. The medical history and laboratory parameters at admission were collected from medical records. Serum thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), thyroid peroxidase antibody, and thyroglobulin antibody were measured, and patients were classified according to thyroid function status. Results. 34.1% of the patients were euthyroid. Length of hospitalization (p<0.001), rate of oxygen demand (p<0.001), and intensive care unit (ICU) admission (p=0.022) were lower, and none of the euthyroid patients died. 108 (52.6%) patients were classified to have ESS, 57 were classified as mild, and 51 were moderate. The inflammatory parameters were higher in patients with moderate ESS. In cluster analysis, a high-risk group with a lower median FT3 value (median = 2.34 ng/L; IQR = 0.86), a higher median FT4 value (median = 1.04 ng/dL; IQR = 0.33), and a lower median TSH value (median = 0.62 mIU/L; IQR = 0.59) included 8 of 9 died patients and 25 of the 31 patients that were admitted to ICU. Discussion. Length of hospitalization, oxygen demand, ICU admission, and mortality were lower in euthyroid patients. Moreover, none of the euthyroid patients died. In conclusion, evaluation of thyroid function tests during COVID-19 infection may give information about the prognosis of disease.Publication Metadata only Comparison of intravenous and non-intravenous antibiotic regimens in eradication of P. aeruginosa and MRSA in cystic fibrosis(WILEY, 2021-12) KARAHASAN, AYŞEGÜL; Mursaloglu, H. Hakan; Akin, Can; Yegit, Cansu Yilmaz; Ergenekon, Almala P.; Uzunoglu, Burcu Suzer; Tastan, Gamze; Gokdemir, Yasemin; Eralp, Ela Erdem; Yagci, Aysegul Karahasan; Karakoc, Fazilet; Karadag, BulentBackground Chronic pulmonary infection is the leading cause of mortality and morbidity in patients with cystic fibrosis (CF). The most common pathogens isolated in CF are Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Chronic infection of PA and methicillin-resistant S. aureus (MRSA) are associated with worse survival and antibiotic eradication treatment is recommended for both. This study compared the outcomes between intravenous (IV) and non-IV antibiotics in eradication of PA and MRSA. Methods This was a single-center retrospective study. All respiratory specimen cultures of 309 CF patients and eradication regimens between 2015 and 2019 were reviewed. Patients received eradication treatment in case of first ever isolation or new isolation after being infection-free >= 1 year. The primary analysis was the comparison of the percentage of successful eradication after receiving IV and non-IV eradication regimens. Demographic and clinical risk factors for eradication failure were also analyzed. Results One hundred and two patients with PA isolations and 48 patients with MRSA were analyzed. At 1 year, 21.6% in PA group and 35.4% in MRSA group were successfully eradicated. There was not any statistically significant difference between IV versus non-IV antibiotic regimens on eradication in either group. Additionally, none of the clinical risk factors was significantly associated with eradication failure in PA and MRSA groups. Conclusion In the eradication of PA and MRSA, IV and non-IV treatment regimens did not show any superiority to one another. Non-parenteral eradication could be a better option considering the cost-effectiveness and the treatment burden of IV treatments due to hospitalization and the need for IV access.Publication Open Access Demographic features and laboratory parameters among hospitalized vaccinated patients with covid-19 in Istanbul, Turkey(2023-05-01) KARAHASAN, AYŞEGÜL; Karahasan A.BackgroundThe number ofCOVID-19cases has been decreasing recently, and the restrictions are waived in many countries. The data aboutvaccineefficacy are essential to be prepared for the future even if the pandemic ends and the disease becomes endemic.AimsThe aim of this study was to define demographic and laboratory data for disease severity among vaccinatedCOVID-19cases who were hospitalized.Study DesignThis is a retrospective cohort study.MethodsSARS-CoV-2 polymerase chain reaction–positive patients who were fully vaccinated (2 doses of vaccines and 3 doses of vaccines) and had been hospitalized at least 15 days after the lastvaccinedose were enrolled in this study. Patients\" data including laboratory parameters were retrieved, and descriptive statistics and comparison of variables were calculated.ResultsBetween September 1, 2021, and February 28, 2022, 685 patients (mean age, 67.84 years; 50.8% female) were hospitalized. Inactivated whole-virion SARS-CoV-2vaccine(CoronaVac) had been administered to 467 of the patients (68.4%), BNT162b2 mRNAvaccine(Pfizer-Pfizer-BioNTech) had been administered to 107 of the patients (15.6%), and to 111 of the patients (16%), a combination of 2 vaccines had been administered. At least 1 comorbidity was present in 160 participants (23%) and more than 4 comorbidities in 46 patients (6.6%). The most common comorbidity was hypertension (349, 50.2%). The presence of comorbidities was significantly higher in patients having 3 doses ofvaccine. Increased ferritin levels were determined in 56.4% of the patients, increased D-dimer levels in 69.9% of the patients, increased C-reactive protein levels in 79.7% of the patients, and increased procalcitonin levels in 61.5% of the patients. A total of 36.4% of the patients had decreased lymphocyte counts, 20% had low lymphocyte/monocyte ratio, and 22% had decreased neutrophil/lymphocyte ratio. The only parameter that was significantly higher in patients having 3vaccinedoses was procalcitonin. Mean duration of hospitalization was 9.68 ± 7.29 days. In the CoronaVac and Pfizer-BioNTech groups, 68.5% and 21.4%, respectively, of the patients were older than 65 years. Seventeen (3.6%) patients in the CoronaVac group, 6 (5.4%) patients in the combination group, and 3 (2.8%) patients in Pfizer-BioNTech group had been admitted to the intensive care unit. Mortality rate was 0.3% (2 of 685 patients).ConclusionsThe incidence of severeCOVID-19disease among fully vaccinated patients is low even in the presence of comorbidities, older age, and presence of abnormal laboratory parameters, regardless of thevaccinetype.Publication Open Access Molecular analysis of human adenoviral keratoconjunctivitis cases: Results of a 2-year survey(2023-01-01) KARAHASAN, AYŞEGÜL; Karahasan A.
- «
- 1 (current)
- 2
- 3
- »